Thyroid Cancer Mutation Panel
Use
This test is designed to detect mutations in molecular markers associated with papillary and follicular thyroid cancer—specifically BRAF V600E, RAS, RET/PTC, and PAX8/PPAR gamma—in fine‑needle aspiration biopsy specimens with indeterminate cytology, to inform clinical decision‑making and potentially avoid unnecessary surgical removal of healthy thyroid tissue.
Special Instructions
Used on FNA biopsy samples; complements routine cytology for indeterminate thyroid biopsies; aligns with American Thyroid Association guidelines as a clinical aid in managing indeterminate thyroid biopsy results.
Limitations
Limited to the four markers specified (BRAF V600E, RAS, RET/PTC, PAX8/PPAR gamma); may not detect mutations outside those loci; sample adequacy (e.g., insufficient cellular content) can reduce detection capability; presence of one mutation generally mutually exclusive but hierarchical screening may be necessary when tissue is limited.
Methodology
Other
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Not provided.